Price
CHART BY
Frequently asked questions
What is Nanobiotix's market capitalization?
The market capitalization of Nanobiotix is 921.04M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Nanobiotix?
Nanobiotix's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.737. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Nanobiotix's stock?
Currently, 7 analysts cover Nanobiotix's stock, with a consensus target price of 19.37. Analyst ratings provide insights into the stock's expected performance.
What is Nanobiotix's revenue over the trailing twelve months?
Over the trailing twelve months, Nanobiotix reported a revenue of 36.22M.
What is the EBITDA for Nanobiotix?
Nanobiotix's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -26.81M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Nanobiotix?
Nanobiotix has a free cash flow of -8.73M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Nanobiotix have, and what sector and industry does it belong to?
Nanobiotix employs approximately 108 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Nanobiotix's shares?
The free float of Nanobiotix is 46.30M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- 921.04M
- EPS (TTM)
- -$0.737
- Free Float
- 46.30M
- Revenue (TTM)
- 36.22M
- EBITDA (TTM)
- -26.81M
- Free Cashflow (TTM)
- -8.73M
Pricing
- 1D span
- $19.76$22.38
- 52W span
- $2.804$29.63
Analyst Ratings
The price target is 19.37 and the stock is covered by 7 analysts.
Buy
7
Hold
0
Sell
0
Information
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
- Employees
- 108
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- FR0011341205
- Primary Ticker
- NANO
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet